

Advisory Committee on Immunization Practices (ACIP): Mumps Work Group

Kelly L. Moore MD, MPH
Director, Tennessee Immunization
Program
Chair, Mumps ACIP Work Group

ACIP Meeting
June 22, 2017

Mumps Work Group

Terms of Reference

Objective

- Evaluate and propose policy options to prevent or control mumps outbreaks in the United States

Activities

- Review epidemiology of mumps in the 2-dose vaccine era, including the international experience
- Review available evidence on duration of immunity for mumps after 2 doses of MMR and other risk factors for vaccine failure
- Review available evidence on impact of a 3rd dose of MMR for mumps outbreak control
- Evaluate programmatic implications and cost of various policy options for a 3rd dose of MMR to prevent or control mumps outbreaks

Mumps Work Group

Evidence Review

- March-June 2017: biweekly conference calls (6 calls x 1.5h) & 1 on-line survey
- Reviewed literature and unpublished data on
 - Mumps epidemiology in the United States in the 2-dose era
 - Immune response to mumps virus and mumps vaccination
 - Persistence of immune response after 2-dose vaccination
 - 2-dose vaccine effectiveness and risk factors for vaccine failure
 - Molecular epidemiology and antigenic differences between vaccine and circulating mumps strains
 - Immune response to a 3rd dose of MMR vaccine
 - Clinical studies after administration of a 3rd dose of MMR vaccine
 - 3rd dose for mumps outbreak control
 - Safety of the 3rd dose
 - US military experience with mumps disease and vaccination

Mumps Work Group Timeline

- **February 2017**
 - Informed ACIP of the Mumps Work Group and terms of reference
 - Overview of US mumps recommendations and epidemiology
- **June 2017**
 - Update on mumps epidemiology in the United States in 2017
 - Evidence reviewed by the Work Group concerning laboratory and clinical studies of the 3rd dose of MMR vaccine
- **October 2017**
 - Summarize the evidence reviewed by the Work Group and present Work Group interpretation of the evidence
- **February 2018:**
 - Present additional evidence from ongoing studies e.g., cost of various policy options
 - Present Work Group considerations/opinions, ACIP vote

Mumps Work Group Members

ACIP

Kelly Moore, Chair
Paul Hunter
Cynthia Pellegrini
Jose Romero

Consultants

Huong McLean
Patricia Quinlisk
Jane Seward
Stanley Plotkin*

Ex Officio Members & Liaison Representatives

Carol Baker (IDSA)
Chas DeBolt (CSTE)
Shalini Desai (NACI)
Susan Even (ACHA)
Amy Groom (IHS)
Melissa Martinez (AAFP)
Dawn Nolt (AAP/COID)
Steven Rubin (FDA/CBER)
Jane Zucker (AIM)

CDC

Mona Marin, CDC lead
Tracy Ayers
Nakia Clemmons
Carole Hickman
Manisha Patel
Paul Rota
Janell Routh
Melinda Wharton
Patricia Wodi
Fangjun Zhou
Adria Lee

*expert consultant on scientific discussions

June 22, 2017: ACIP Mumps Session

Topic	Speaker
Update on Mumps Work Group activities	Dr. Kelly Moore ACIP/Tennessee Immunization Program
Update on mumps epidemiology in the United States, 2017 and review of studies of 3 rd dose of MMR vaccine	Dr. Mona Marin, CDC
Effectiveness of the 3 rd dose of MMR vaccine in a mumps outbreak in a highly vaccinated university population, Iowa, 2015-2016	Dr. Cristina Cardemil, CDC